Anticancer Agent Shikonin Is an Incompetent Inducer of Cancer Drug Resistance

Open Access

Peer-reviewed

Research Article

Hao Wu,

Affiliation Cancer Institute, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⨯
Jiansheng Xie,

Affiliation Cancer Institute, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⨯
Qiangrong Pan,

Affiliation Cancer Institute, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⨯
Beibei Wang,

Affiliation Cancer Institute, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⨯
Danqing Hu,

Affiliation Cancer Institute, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⨯
Xun Hu

* E-mail: huxun@zju.edu.cn

Affiliation Cancer Institute, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⨯

Reader Comments (0)

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Oncology agents
Is the Subject Area "Oncology agents" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Drug research and development
Is the Subject Area "Drug research and development" applicable to this article?

Thanks for your feedback.
MTT assay
Is the Subject Area "MTT assay" applicable to this article?

Thanks for your feedback.